To elucidate the possible role of genetic variation in androgen receptor (AR), estrogen receptor ␣ (ER␣), and ER␤ on serum androgen levels in premenopausal women, the CAG repeat polymorphism of the AR gene, the TA repeat polymorphism of the ER␣ gene, and the CA repeat polymorphism of the ER␤ gene were studied in a populationbased cohort of 270 women. Total testosterone, free testosterone, dehydroepiandrosterone sulfate, androstenedione, 17-hydroxyprogesterone, 3␣-androstanediol glucuronide, 17␤-estradiol, LH, FSH, and sex steroid hormone-binding globulin (SHBG) were measured in serum samples obtained in the follicular phase of the menstrual cycle. Women with relatively few CAG repeats in the AR gene, resulting in higher transcriptional activity of the receptor, displayed higher levels of serum androgens, but lower levels of LH, than women with longer CAG repeat sequences. The CA repeat of the ER␤ gene also was associated with androgen and SHBG levels; women with relatively short repeat regions hence displayed higher hormone levels and lower SHBG levels than those with many CA repeats. In contrast, the TA repeat of the ER␣ gene was not associated with the levels of any of the hormones measured. Our results suggest that the serum levels of androgens in premenopausal women may be influenced by variants of the AR gene and the ER␤ gene, respectively. (J Clin Endocrinol
T HE PHYSIOLOGICAL and pathophysiological roles of androgens in women are gaining increasing attention. Recent studies thus suggest an important role of testosterone in conditions such as the polycystic ovary (PCO) syndrome (1, 2) , recurrent miscarriages (3, 4) , androgenic alopecia, hirsutism, acne (5) , reduced libido (6) , and various psychiatric conditions (7) . Of particular interest in this context are the accumulating data suggesting that elevated levels of androgens may be a major risk factor for the development of noninsulin-dependent diabetes mellitus in women (8) .
The androgen receptor (AR) belongs to a family of nuclear transcription factors. The AR gene is located on chromosome Xq11-12. A polymorphic polyglutamine stretch in the aminoterminal domain of the AR, encoded by the nucleotides cysteine, adenine, and guanine (CAG), appears to influence the function of the receptor as a transcription factor, so that relatively long fragments are associated with a low level of receptor function (9 -11) . The polyglutamine region is assumed to be involved in interactions between the AR and different coactivators; recent data suggest that long repeat regions are inhibitory to these interactions, which could explain the lower activity of the receptor (12) .
Clinical studies support the functional importance of the CAG repeat sequence of the AR gene. Relatively few (Ͻ22) CAG repeats in the AR gene are hence associated with a higher risk of prostate cancer (13, 14) , benign prostate hyperplasia (15, 16) , and young-onset rheumatoid arthritis (17) and with a lower risk of infertility (18) . A substantial expansion (40 -72 repeats) of the CAG repeat sequence is the cause of a rare X-linked form of motor neuron disorder in men, termed Kennedy's disease (spinal and bulbar muscular atrophy) (19) , that is associated with some degree of androgen insensitivity (20) . Data on the functional importance of the number of CAG repeats in the AR gene in women is sparse, but associations between this polymorphism and hirsutism, acne, androgenic alopecia (21, 22) , bone mass density (23) , and breast cancer (24, 25) have been suggested.
In men, the inhibitory feedback influence of the AR on serum levels of androgens is well established and is illustrated by the marked elevation of testosterone levels after the administration of an AR antagonist (26) and by the reduction in endogenous androgen production after intake of exogenous androgens (27) . The report by Krithivas and co-workers (28) that a relatively long CAG repeat sequence counteracts the age-related decline in serum androgen levels hence supports the idea that many CAG repeats are associated with low AR responsiveness. In line with this, patients with Kennedy's disease are reported to fail to suppress LH and testosterone levels after the administration of a synthetic androgen (20) . In women, the hypothalamus-pituitarygonadal axis is mainly regulated by female sex steroids; to what extent and by which mechanisms androgen receptors may influence serum androgen levels in women are thus less obvious.
Two estrogen receptors (ERs) have been identified, the ␣ subtype and the more recently discovered ␤ subtype (29) . The ER␣ gene is located on chromosome 6q25-27. Its promoter region contains a polymorphic TA repeat (30) that has been associated with coronary heart disease (31) and anxiety (32) in men and with bone mineral density (33, 34) , familiar premature ovarian dysfunction (35) , and endometriosis (36) in women. The ER␤ gene is located on chromosome 14q23-24. Recently, a polymorphic dinucleotide CA repeat in the noncoding 3Ј-portion of the gene was identified (37) and was suggested to be associated with bone mineral density in women (38) . The functional importance of these two polymorphisms has as yet not been clarified; however, as suggested (39) , there are reasons to believe that repeat nucleotide sequences (micro/minisatellites), even when situated in untranslated regions, per se may influence the expression of a gene.
The idea that estrogens may influence serum androgen levels in women gains support from the reduction in serum levels of ovarian and adrenal androgens observed in women receiving estrogen replacement therapy during menopause (40, 41) or oral contraceptives (42) . The involvement of the ␣ and ␤ receptor subtypes, respectively, in the tentative effect of estrogens on androgen levels is not known however.
In this study we explored to what extent serum levels of sex steroids, sex hormone-binding globulin (SHBG), LH, and FSH in a population-based cohort of women are related to the number of CAG repeats of the AR gene, the number of TA repeats of the ER␣ gene, and the number of CA repeats of the ER␤ gene.
Subjects and Methods Subjects
All women born on uneven days in 1956 and living in Goteborg, Sweden, constituted the primary cohort (n ϭ 1137) (43, 44) . Of these subjects, 80% responded to questionnaires and reported self-measurements of body weight, height, and circumferences over the waist and hips. The participants in the present study were originally recruited to elucidate the relationship between the waist/hip circumference ratio (WHR) and various metabolic and endocrine parameters. To ensure that the subjects included displayed a considerable variation with respect to WHR, self-measured WHR (as reported by the subjects) was used for selection of subjects; thus, one third reported low (Ͻ0.738) self-rated WHR, one third reported a self-measured WHR around the median (0.798 -0.822), and one third reported high (Ͼ0.895) self-measured WHR. Women who had not experienced menstruation during the past 6 months were excluded. In total, 450 women were invited to participate. Two hundred and seventy (60%) of these agreed to provide blood samples for hormone analyses and genotyping. Probably due to the fact that 1) the inclusion of subjects was based on self-rated rather than verified WHR, 2) 2 yr had elapsed between the return of the questionnaire and the assessment of WHR in the laboratory, and 3) 40% of those selected refused to provide blood samples, the laboratory-assessed WHR data in the studied population appeared to be normally distributed, with a median corresponding to that of the normal population. It is hence reasonable to assume that this cohort of women does not differ substantially from the normal population with respect to WHR. Moreover, as reported in previous publications (43, 44) , the subjects included did not differ to any greater extent from those 40% who refused to participate with respect to parameters such as body mass index, somatic health, mental health, and a number of socioeconomic factors. Subjects using oral or im hormone-containing contraceptives (n ϭ 26) were excluded from analysis; these are hence based on a total number of 244 participants. All but 17 subjects (7%) were from Europe and of probable Caucasian origin. Of the non-Europeans, 14 were from the Middle East, 2 were from South America, and 1 was from South-East Asia. No attempt to further analyze the ethnicity of the participants was made. Fasting blood samples for hormonal measurements (serum) and genetic analyses (whole blood) were obtained in the follicular phase of the menstrual cycle (days 5-10). All women provided written informed consent. The study was approved by the ethical committee of Goteborg University.
Genotyping
Genomic DNA was isolated using the QIAamp DNA Blood Mini Kit (QIAGEN, Valencia, CA). The three different regions were amplified by PCR. The PCR of the CAG repeat in the AR gene was performed in a total volume of 25 L containing 50 ng DNA, 1.5 mmol/L MgCl 2 , 0.625 U AmpliTaq DNA polymerase (Perkin-Elmer Corp., Norwalk, CT), and 0.2 mol/L of each of the primers (5Ј-GTG CGC GAA GTG ATC CAG A-3Ј and 5Ј-GTT TCC TCA TCC AGG ACC AGG TA-3Ј, selected with Primer Express, Perkin-Elmer Corp.). The forward primer was fluorescently labeled with 6-carboxy fluorescein. Nucleotides promoting the nontemplated addition of adenine by Taq DNA polymerase was added to the 5Ј-end of the reverse primer (45) . Thermal cycling was performed in a Perkin-Elmer Corp. GeneAmp PCR System 9700 with the following temperature profile: 95 C for 5 min, followed by 35 cycles of 95 C for 30 s, 57 C for 30 s, 72 C for 30 s, and a final incubation at 72 C for 7 min.
The PCR of the TA repeat of the ER␣ gene was performed in a total volume of 15 L containing 50 ng DNA, 1.5 mmol/L MgCl 2 , 1 U HotstarTaq polymerase (QIAGEN), and 0.3 mol/L of each of the primers described by Comings and co-workers (32) . The forward primer (5Ј-AGA CGC ATG ATA TAC TTC ACC-3Ј) was labeled with 6-carboxy fluorescein and used together with the reverse primer (5Ј-GTT CAC TTG GGC TAG GAT AT-3Ј). The temperature profile was 95 C for 15 min, followed by 35 cycles of 95 C for 30 s, 60 C for 30 s, 72 C for 30 s, and a final incubation at 72 C for 7 min.
The PCR of the CA repeat polymorphism of the ER␤ gene was performed in a total volume of 25 L containing 50 ng DNA, 1.5 mmol/L MgCl 2 , 1 U AmpliTaq DNA polymerase (Perkin-Elmer Corp.), and 0.3 mol/L of each of the primers described by Tsukamoto and co-workers (37) . The forward primer (5Ј-GGT AAA CCA TGG TCT GTA CC-3Ј) was labeled with Hexachloro-6-carboxy fluorescein and used together with the reverse primer (5Ј-AAC AAA ATG TTG AAT GAG TGG G-3Ј). The temperature profile was 95 C for 12 min, followed by 35 cycles of 95 C for 30 s, 60 C for 30 s, 72 C for 30 s, and a final incubation at 72 C for 7 min.
The fluorescently labeled DNA fragments were analyzed by size with automated capillary electrophoresis using an ABI PRISM 310 Genetic Analyzer (Perkin-Elmer Corp.).
Hormone determination
17␤-Estradiol, total testosterone, SHBG, and FSH were analyzed using a chemiluminescent enzyme immunoassay; androstenedione, dehydroepiandrosterone sulfate (DHEA-S), 17-hydroxyprogesterone, 3␣-androstanediol glucuronide (3-␣-diol-G), and LH were analyzed by RIA. All assays were performed in accordance with the instructions provided by the manufacturer (3-␣-diol-G: Diagnostics Systems Laboratories, Inc., Webster, TX; LH: MAIA Clone, Serono Diagnostics, Braintree, MA; all other: Diagnostic Products, Los Angeles, CA).
Data analysis
Prompted by previous studies suggesting an inverse relation between the number of CAG repeats in the AR and receptor activity, we divided all alleles into two groups of approximately equal size; those with 19 or fewer repeats were defined as short (S), whereas those with more than 19 repeats were defined as long (L). The subjects studied could thus be divided into three groups [those with two short alleles (SS), those with two long alleles (LL), and those with one short and one long allele (SL)] that were compared with respect to serum hormone levels. Given the fact that the AR gene is located on the X-chromosome, resulting in a random inactivation of one of the two alleles in women (46), we also decided to analyze the tentative importance of carrying at least one allele with a short CAG repeat fragment (a more active receptor); to this end, all subjects were divided into two groups, based on the length of the shortest of the two alleles they displayed. So that these two groups should be of approximately the same size, the cut-off used for this operation was 17 (Յ17 ϭ short). Likewise, a division based on the length of the longest of the two alleles was performed, with 20 as the cut-off (Յ20 ϭ short).
For the ER␣ and ER␤ gene polymorphisms studied, no relationship between repeat number and function has as yet been found. Prompted by the tentative assumption that there is a relationship between the length of microsatellites and function (39) , the ER␣ and ER␤ alleles were examined using the same strategy as that applied for the AR gene data, i.e. by splitting the subjects into subgroups comprising those with 2 short alleles (SS), those with 2 long alleles (LL), and those with 1 short and 1 long allele (SL). Splitting of groups was undertaken with the median as the cut-off, hence yielding groups of approximately the same size. These cut-off limits were 191 (alleles containing Յ191 bp ϭ short) for ER␣ and 159 (alleles containing Յ159 bp ϭ short) for ER␤.
Data are presented as the mean Ϯ se. Comparisons of groups were undertaken using t test (two groups) or ANOVA, followed by Fischer's protected least significant difference test (Ն2 groups). P ϭ 0.05 was considered statistically significant.
Results

AR
The CAG repeats in the AR receptor ranged from 4 to 33 CAGs, with a median length of 19 ( Fig. 1) . As shown in In addition to the analysis based on a cut-off limit of 19, we performed post-hoc analyses using 17 (SS, n ϭ 19; LL, n ϭ 123; SL, n ϭ 97), 18 (SS, n ϭ 46; LL, n ϭ 77; SL, n ϭ 116), and 20 (SS, n ϭ 115; LL, n ϭ 27; SL, n ϭ 97) CAG repeats as cut-off limits, respectively. The association between repeat length and total testosterone levels were significant using all these cut-off limits; the highest level of significance was observed with a cut-off of 18 (SS vs. LL, P ϭ 0.0006; SS vs. SL, P ϭ 0.08; SL vs. LL, P ϭ 0.02). Also the possible relationship between AR genotype and gonadotropin levels was assessed using these alternative cut-off limits. These analyses revealed a significant association between genotype and LH levels also when the splits were undertaken using 18 (data not shown) and 20 (SS vs. LL, P ϭ 0.0009; SS vs. SL, P ϭ NS; SL vs. LL, P ϭ 0.01) as cut-off limits, respectively. The association between AR genotype and FSH levels was significant using S ϭ 20 as the cut-off limit (SS vs. LL, P ϭ 0.03; SS vs. SL, P ϭ NS; SL vs. LL, P ϭ 0.05).
Comparison of the two groups formed by dividing the subjects with respect to the length of the shortest of the two AR gene CAG repeat polymorphisms carried by each individual revealed a significant difference between those with a short (Յ17) shortest allele (n ϭ 116) and those with a long (Ͼ17) shortest allele (n ϭ 123), not only with respect to total testosterone (short, 2.3 Ϯ 0.1; long, 1.8 Ϯ 0.1; P ϭ 0.002), but also with respect to free testosterone (short, 5.2 Ϯ 0.3; long, 4.3 Ϯ 0.2; P ϭ 0.005) and 17␣-hydroxyprogesterone (short, 4.2 Ϯ 0.2; long, 3.4 Ϯ 0.1; P ϭ 0.003). Androstenedione levels were also higher in the group displaying at least one short allele, but this difference failed to reach statistical significance (short, 7.8 Ϯ 0.4; long, 7.0 Ϯ 0.2; P ϭ 0.06). Serum levels of DHEA-S, 3␣-diol-G, 17␤-estradiol, LH, FSH, and SHBG did not differ between groups (data not shown). The corresponding analysis after splitting for the longest allele in each individual (cut-off limit, 20; short allele, n ϭ 115; long allele, n ϭ 124) revealed a significant difference with respect to total testosterone (short, 2.2 Ϯ 0.1; long, 1.9 Ϯ 0.08; P ϭ 0.008) and LH (short, 3.6 Ϯ 0.2; long, 4.7 Ϯ 0.4; P ϭ 0.03), but with respect neither to the other hormones nor to SHBG (data not shown). 
ER␣
Eighteen different alleles of the ER␣ gene were identified, comprising 183-217 bp (Fig. 3) . Cut-off limit was 191. Comparison of the SS (n ϭ 78), LL (n ϭ 67), and SL (n ϭ 99) groups with respect to the levels of total testosterone (SS, 
ER␤
Fourteen different alleles of the ER␤ gene were identified, comprising 145-171 bp (Fig. 4) . The cut-off limit was 159.
Comparison of the SS (n ϭ 43), LL (n ϭ 74), and SL (n ϭ 124) groups revealed a significant difference with respect to total testosterone ( In the same way as described for AR, the possible relationship between ER␤ genotype and hormonal levels was assessed using alternative cut-off limits (157 and 161, respectively). The associations between levels of total testosterone and genotype reported above remained significant when using these cut-off limits (data not shown).
Subgroup analyses
The fact that self-measured WHR was used as an inclusion criterion when initially recruiting this cohort of women (see Materials and Methods) prompted us to investigate to what extent the observed relationships between genotypes and hormonal levels were restricted to women with high or low WHR, respectively. These analyses, however, showed that WHR seems not to be a factor of importance in this context; similar associations were hence observed in women with low or high WHR, respectively (data not shown). In addition, all calculations were repeated after excluding those 17 subjects that were not of European origin; in no case did the exclusion of these subjects influence the level of significance (data not shown).
Discussion
The data presented in this paper suggest that serum androgen levels in women are associated with a CAG repeat polymorphism in the AR gene and by a CA repeat polymorphism in the ER␤ gene. To our knowledge, such an association between receptor genes and androgen levels in women has previously not been reported.
The observation that variants of the AR gene coding for a more active receptor (few CAG repeats) are associated with higher levels of androgens is the opposite of what has previously been reported in men (28) and suggests that the major influence of ARs on androgen production in women is stimulatory rather than inhibitory. Serum levels of LH were significantly lower in subjects with few CAG repeats in the AR gene, suggesting that ARs in women exert an inhibitory influence on LH release during the follicular phase. This observation indicates that the relative increase in serum androgen levels in these subjects is not mediated by the hypothalamus, but is due to a direct effect of ARs in the adrenal glands or the ovaries. It should, however, be underlined that LH is secreted in a pulsatile fashion; any information based on a single sample should hence be interpreted with caution.
ARs have been demonstrated in the adrenal gland (47) . Administration of testosterone to women has been shown to cause increased serum levels of adrenal androgens (48 -51) , which may explain the increase in adrenal androgens observed in women with the PCO syndrome (52, 53) . The assumption that the observed positive relationship between a gene polymorphism coding for a more active receptor and high levels of testosterone should be due to an increase in adrenal androgen production is, however, to some extent challenged by the observation that serum levels of an androgen that is generally regarded as a marker of adrenal androgen production, DHEA-S, did not seem to be related to the AR gene.
Human thecal cells, which are thought to be the primary site of androgen biosynthesis in the ovarian stroma, have been shown to express ARs (54) . Recent data suggest that short-term androgen treatment stimulates follicle development by various mechanisms (55) (56) (57) . Supporting the idea that androgens may induce ovarian overgrowth, leading to further hyperandrogenism, androgen-producing tumors, congenital hyperplasia, and exogenous androgen treatment have all been associated with the development of PCO. On the other hand, AR blockade has been shown to cause a reduction in follicle number and ovarian size in women with this condition (58) . The present observation that women expressing a more active AR display higher serum levels of androgens may thus reflect an enhanced androgenic influence on androgen-producing cells in the ovary. No examination of ovarian morphology was undertaken in this trial; the possible relationship between the genes studied and PCO was hence not the subject of this investigation. It should however be underlined that women with amenorrhea, which is a common feature of a manifest PCO syndrome, were not included in this study.
Lending further support for the idea that the AR indeed exerts a stimulatory influence on androgen production in women, administration of the AR antagonist flutamide has been shown to reduce androgen levels (58 -60) . Whether this effect is exerted within the adrenal gland or within the ovaries, however, remains to be clarified. Also, results obtained with flutamide should be interpreted with caution, because a direct, non-AR-mediated influence of flutamide on testosterone synthesis cannot be excluded (61, 62) .
The present data suggest that the ER␤ gene influences androgen levels. Women with a short CA repeat region of the ER␤ gene hence displayed higher serum levels of total and free testosterone than women with many CA repeats. In contrast, no associations between the ER␣ polymorphism studied and serum levels of sex steroids were observed.
Several studies suggest that estrogen replacement therapy (ERT) of postmenopausal women (63) or administration of oral contraceptives (42) reduces androgen levels. This effect may be mediated by the hypothalamus, but direct effects on the ovaries have been suggested as well. Notably, ER␤ receptors have been detected in the ovaries, adrenals, pituitary, and hypothalamus of humans (64) and monkeys (65) .
Our finding that SHBG levels seem related to the ER␤ gene is in agreement with previous studies reporting a profound stimulatory influence of estrogens on SHBG production (40, 41, 63) . The observed association between a low number of CA repeats in the ER␤ gene and low levels of SHBG may explain the finding that free testosterone levels seemed more strongly associated with this gene than did total levels of testosterone.
The apparent association between a short CA repeat region of the ER␤ gene and high and low levels of testosterone and SHBG, respectively, would suggest that this variant of the gene leads to a less active receptor (which contrasts with the fact that a short repeat region of the AR is known to lead to a more active receptor). Needless to say, a detailed discussion of the possible mechanisms underlying the apparent association between the ER␤ gene polymorphism studied and hormone levels must await a further clarification of the putative influence of this polymorphism on receptor function.
As discussed above, the apparent influence of the AR and ER␤ genes on androgen levels may be explained by acute effects of these receptors on the hormonal production in the adrenal glands and/or the ovaries. As both AR and ER␤ are probably involved in the prenatal sexual differentiation (66, 67) , the possibility that the effects observed are due to early organizational effects of these receptors, however, may not be excluded. The possibility that a relatively pronounced influence of androgens during development leads to an increase in serum androgen levels in the adult woman should be considered.
It should be noted that all blood samples were obtained in the follicular phase of the menstrual cycle. The fact that no relationship between the three gene polymorphisms studied and serum levels of 17␤-estradiol was observed does not preclude that such associations would have been found if hormonal levels had been followed throughout the menstrual cycle. Moreover, although androgen levels are more stable than are the levels of female sex steroids, the possibility that serum levels of androgens are also regulated by different mechanisms during different phases of the cycle cannot be excluded. The possibility that the ER␣ genotype are more important for hormonal levels in phases of the cycle when estrogen levels are high than during the early follicular phase also should not be excluded.
In conclusion, our results suggest that serum levels of androgens in premenopausal women may be influenced by certain variants of the AR gene and the ER␤ gene, respectively. Given the likely involvement of androgens for somatic and psychiatric morbidity in women, a further elucidation of the genetic determinants for serum androgen levels is clearly warranted.
